Joshua Sabari, MD, discusses lurbinectedin maintenance candidacy, supportive care strategies, and the critical need for ...

A single cilta-cel infusion after fludarabine/cyclophosphamide produced 100% MRD negativity at 10⁻⁶ by month 2, sustained at ...

Pelareorep combined with FOLFIRI and bevacizumab produced a 19.5-month median duration of response and 33% ORR in second-line ...

Rashmi Chugh, MD, discusses the outcomes and goals of a promising study for ozekibart plus chemotherapy in patients with ...

FDA cleared once-daily ruxolitinib XR for MF, HU-refractory/intolerant PV, and steroid-refractory acute/chronic GVHD after ...

As advanced therapies continue to move beyond academic medical centers, the success of this transition will increasingly ...

In the ARES trial, MaaT013 led to improvement in refractory lower GI chronic GVHD, a key unmet need in patients receiving ...

Dr. Evan Wu presents William, a 76-year-old Black man and former smoker (25 pack-year history, quit 15 years ago) who ...

A data monitoring committee recommended stopping FLASH2, a randomized double-blind placebo-controlled confirmatory phase 3 ...

Dr Dulmage highlights that one of the most frequently overlooked early warning signs of clinically significant dermatologic ...

Kelly, MD, MBA, and participants discussed key considerations for biomarker testing in upper GI cancers. Biomarker status has ...

Amandeep Salhotra, MD, of City of Hope National Medical Center in Duarte, California, discusses the impactful conclusions ...